⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17793402 | 0.81 | — | — | |
| SCHEMBL9963260 | 0.80 | HSD11B1 (0.39) | — | |
| SCHEMBL13697437 | 0.80 | GRIN2D (0.37) | — | |
| SCHEMBL18633580 | 0.80 | HSD11B1 (0.33) | — | |
| SCHEMBL14873763 | 0.80 | HSD11B1 (0.37) | — | |
| SCHEMBL13352429 | 0.77 | HSD11B1 (0.39) | — | |
| SCHEMBL3919485 | 0.77 | TSHR (0.41) | — | |
| SCHEMBL19200430 | 0.77 | HSD11B1 (0.37) | — | |
| SCHEMBL2355397 | 0.76 | — | — | |
| SCHEMBL5720694 | 0.75 | LMNA (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024092115-A2 | MK2 INHIBITORS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-05-02 | — | — | WO | disclosed |
| US-20200163336-A1 | CYCLIC AMINE COMPOUND AND PEST CONTROL AGENT | NIPPON SODA CO., LTD. (JP) | 2020-05-28 | — | — | US | disclosed |
| EP-3309148-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2018-04-18 | — | — | EP | disclosed |
| WO-2018067615-A1 | COMPOUNDS, DEVICES, AND USES THEREOF | SIGILON THERAPEUTICS, INC. (US) | 2018-04-12 | — | — | WO | disclosed |
| US-9738655-B2 | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-08-22 | — | — | US | disclosed |
| EP-2766346-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-29 | — | — | EP | disclosed |
| US-20170073330-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-03-16 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-9556148-B2 | N-cyanomethylamides as inhibitors of janus kinase | CADILA HEALTHCARE LIMITED (IN) | 2017-01-31 | — | — | US | disclosed |
| US-20160318904-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-03 | — | — | US | disclosed |
| EP-2206707-B1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-07-23 | — | — | EP | disclosed |
| US-20130231321-A1 | 2-SUBSTITUTED-ETHYNYLTHIAZOLE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-09-05 | — | — | US | disclosed |
| US-8440837-B2 | 2-substituted-ethynylthiazole derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-05-14 | — | — | US | disclosed |
| WO-2013056060-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-8304547-B2 | Azolecarboxamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2012-11-06 | — | — | US | disclosed |
| US-20120157432-A1 | NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME, CORP. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011103715-A1 | TASK CHANNEL ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20100249088-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2206707-A1 | AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |